Form 4: Baker Bros. Advisors Reports Incyte Director Stock Grant

Baker Bros. Advisors and affiliated entities reported the acquisition of Incyte Corp common stock by Julian C. Baker in lieu of director fees, detailing complex beneficial ownership structures.

Summary

• Julian C. Baker, a director of Incyte Corp, received 388 shares of common stock on September 30, 2025.
• These shares were issued in lieu of quarterly director retainer fees of $33,000, under Incyte's Amended and Restated 2010 Stock Incentive Plan.
• The shares of common stock are fully vested upon receipt.
• The filing details the indirect beneficial ownership of these shares and other Incyte securities by Baker Bros. Advisors LP, its general partner Baker Bros. Advisors (GP) LLC, and the investment funds 667, L.P. and Baker Brothers Life Sciences, L.P.
• Julian C. Baker and Felix J. Baker, managing members of Baker Bros. Advisors (GP) LLC, disclaim beneficial ownership of securities held by the Funds except to the extent of their pecuniary interest.
• Following the transaction, indirect beneficial ownership includes 2,817,290 shares (via 667, L.P.) and 28,187,969 shares (via Baker Brothers Life Sciences, L.P.).
• Julian C. Baker directly holds 278,773 shares, and Felix J. Baker directly holds 281,190 shares.
• An additional 33,410 shares are indirectly held via FBB Associates, where Julian C. Baker and Felix J. Baker are sole partners.

Sentiment

Score: 7

Explanation: This Form 4 reports a routine insider acquisition of shares by a director in lieu of cash compensation, indicating alignment of interests. There is no negative news or significant new information that would alter the company's fundamental outlook.

Positives

• Julian C. Baker, a director, elected to receive Incyte common stock in lieu of cash director fees, indicating alignment of interests with shareholders.
• The shares received are fully vested, providing immediate ownership.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Julian C. Baker, Felix J. Baker, Baker Bros. Advisors (GP) LLC, and Baker Bros. Advisors LP disclaim beneficial ownership of securities held by the Funds except to the extent of their pecuniary interest.
• Julian C. Baker serves on the Issuer's board as a representative of 667, L.P. and Baker Brothers Life Sciences, L.P. and their affiliates.

Industry Context

The practice of directors receiving equity in lieu of cash compensation is a common mechanism in the biotechnology and pharmaceutical industries to align management and board interests with those of shareholders, particularly in growth-oriented companies like Incyte. This type of insider transaction is generally viewed positively as it demonstrates confidence in the company's future performance.

Comparison to Industry Standards

• The compensation structure, where a director receives equity in lieu of cash, is a standard practice across many publicly traded companies, particularly in the biotech sector, to align director incentives with shareholder value. This approach is consistent with corporate governance best practices observed at peers such as Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX), where executive and director compensation often includes a significant equity component.

Legal Proceedings

• No legal proceedings are mentioned in this Form 4 filing.

Related Party Transactions

• Julian C. Baker, a director, received 388 shares of Incyte common stock in lieu of director retainer fees.
• The shares are indirectly beneficially owned by entities managed by Baker Bros. Advisors LP, where Julian C. Baker and Felix J. Baker are managing members.
• The filing details complex indirect pecuniary interests of Julian C. Baker and Felix J. Baker through various limited partnerships and general partners (e.g., 667, L.P., Baker Brothers Life Sciences, L.P., FBB Associates).

Stakeholder Impact

• Shareholders: The acquisition of shares by a director in lieu of cash compensation generally signals confidence in the company's future, potentially positively influencing investor sentiment. It also aligns the director's financial interests more closely with those of other shareholders.

Next Steps

• Continued beneficial ownership reporting for future transactions by the reporting persons.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director received shares in lieu of cash compensation. While it indicates alignment of interests, it does not present new material information that would fundamentally alter the investment thesis for Incyte Corp, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Incyte, INCY, Baker Bros. Advisors, Form 4, beneficial ownership, director compensation, stock incentive plan, insider transaction